Knowledge · Natural Compounds

Zinc

Zinc is a trace element; studies show benefits especially for diarrhea and respiratory infections in children, but for colds they contradict each other.

Last updated:

We evaluated 330 human studies on Zinc, including 198 randomised controlled trials and 75 meta-analyses or systematic reviews; the controlled studies include 42,118 participants in total. As of 5 October 2026.

This page as PDF · Summary

1. What Is Zinc? Occurrence, Origin and Forms

Zinc is a trace element that the body cannot produce itself and can store only to a limited extent. It occurs in animal and plant foods and is taken up through the diet, and is additionally supplied as salts or as compounds bound to organic carriers. Supply is common when intake is insufficient; in studies, zinc is examined in contexts such as the common cold, wound healing and diarrhoea in children.

Zinc occurs in soils, water and many foods, especially meat, seafood, legumes and seeds. In the body it is present in many tissues and enzymes.

Zinc is obtained from zinc ores; for supply it is bound to salts or organic carriers, for example as sulfate, gluconate, citrate, picolinate or acetate. In studies these forms are examined individually, at different amounts and over different periods of time, as is zinc oxide for topical use.

Forms and Preparations Studied

  • Zinc sulfate
  • Zinc gluconate
  • Zinc citrate
  • Zinc picolinate
  • Zinc acetate
  • Zinc oxide for topical use

Not covered on this page:

  • Zinc pyrithione in anti-dandruff products, a different compound with cosmetic use
  • Zinc oxide as a UV filter in sunscreens, which serves light protection and is not a zinc supply
  • Zinc in infusion and dialysis solutions, which are not supplied via the gastrointestinal route

2. What Does Zinc Do? Results by Area

AreaResult in controlled studiesStrength of evidenceStudiesParticipants
Respiratory tract infectionsmostly improvedhigh6 meta-analyses · 7 controlled · 7 other3,862
Common coldmostly no differencehigh6 meta-analyses · 4 controlled · 2 other320
Immune functionmixedhigh2 meta-analyses · 7 controlled · 5 other811
Diarrhoea in childrenmixedhigh4 meta-analyses · 5 controlled · 1 other10,933
Skinmostly improvedhigh1 meta-analyses · 4 controlled · 2 other220
Tastemostly no differencemoderate1 meta-analyses · 3 controlled · 2 other123
Wound healingmostly no differenceunclear0 meta-analyses · 2 controlled · 3 other42
Other investigationsmostly improvedhigh41 meta-analyses · 174 controlled · 58 other31,397

How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.

3. What the Studies Show in Detail

Zinc and Respiratory Tract Infections: Human Studies

In adults without known zinc deficiency, zinc somewhat prevented mild respiratory infections in two reviews 1114. Both reviews come from the same working group 1114. In treatment, the symptoms subsided earlier, but the certainty of these data is low 1114. The strongest symptoms were less severe, but the average symptom severity was not 1114. In children under five years, preventive zinc reduced the frequency of pneumonia in one review 12. A larger review found no difference for lower respiratory tract infections in children 4. In a region with zinc deficiency, young children taking zinc gluconate fell ill again less often with lower respiratory tract infections 120. In Laos, preventive or therapeutic zinc did not change the number of respiratory infections in young children 78. US cadets had more symptom-free phases with zinc gluconate, but not fewer medically diagnosed infections 215. In children with pneumonia in hospital, zinc shortened hospital stay in two randomized trials 127168. In a third study, it shortened only cough and runny nose 122. A meta-analysis found fewer deaths from pneumonia in children under five years 3. In adults with COVID-19 in hospital, intensive care need or death occurred less often with zinc acetate 156. This study was small and unblinded 156. Predominantly oral zinc forms such as zinc sulfate, zinc gluconate and zinc acetate were investigated, sometimes also sublingual or intranasal, in varying amounts and durations. Combination products do not allow any statement about zinc alone. Echinacea with zinc and vitamin C shortened upper respiratory infections compared with placebo 90. A tablet with aspirin, promethazine, vitamins, zinc and selenium alleviated symptoms in COVID-19 93. A product with pelargonium extract, honey, propolis and zinc alleviated sore throats in children more than standard treatment 245. An early review also suspects a benefit for SARS-CoV-2; study results for this were still pending 71. The studies in children mostly come from countries with widespread zinc deficiency. They cannot be readily transferred to well-nourished people.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
3 Rouhani et al. 2022meta-analysis · 237,068 participantsZinc supplementation (form not stated); ≥10 mg/day in subgroup analysis; Intervention <11 months, follow-up <1 year; vs. Placebo/control in RCTsMortality from pneumonia: improved (0.70: 0.64, 0.98)
4 Imdad et al. 2023systematic review · 219,584 participantsPreventive zinc supplementation, mostly zinc sulfate syrup; mostly 10 mg to 15 mg daily; median follow-up 26 weeks; vs. no intervention, placebo, or waiting listMortality due to LRTI: improved (RR 0.86, 95% CI 0.64 to 1.15); Morbidity due to LRTI: no difference (RR 1.01, 95% CI 0.95 to 1.08)
11 Hunter et al. 2021systematic review · 5,446 participantsZinc formulations oral, intranasal or sublingual; not reported; not reported; vs. Placebo or active controlRTIs prevented per 100 person-months: improved (5 RTIs per 100 person-months (95% CI 1 to 8, NNT=20)); Symptom duration (days earlier): improved (2 days earlier (95% CI 0.61 to 3.50)); Proportion still symptomatic on day 7: improved (19 more adults per 100 (95% CI 2 to 38, NNT=5))
12 Lassi et al. 2016systematic review · 5,193 participantsZinc supplementation (form not stated); vs. Placebo or controlIncidence of pneumonia: improved (RR 0.87; 95% CI 0.81 to 0.94); Prevalence of pneumonia: improved (RR 0.59; 95% CI 0.35 to 0.99); Incidence of pneumonia by specific clinical criteria: improved (RR 0.79; 95% CI 0.0.71 to 0.88)
14 Hunter et al. 2020systematic review · 3,597 participantsZinc (oral, sublingual, topical nasal); oral 15-45 mg/day; sublingual 45-300 mg/day; nasal 0.09-2.6 mg/day; not reported; vs. Placebo or active controlPrevention of respiratory tract infections: improved (5 mild to moderate RTIs per 100 person-months); Treatment: peak symptom severity: improved (mean difference 1.2 points, 0.7 to 1.7); Treatment: average daily symptom severity: no difference (standardised mean difference 0.2, 0.1 to 0.4)
48 De et al. 2026systematic review · 51 participantsZinc supplementation, therapeutic or prophylactic; heterogeneous dosing, not standardized; variable treatment duration; vs. placebo or control, per studyresolution of respiratory infections: improved (improved the resolution of respiratory infections)
50 Banerjee et al. 2026systematic reviewzinc (form not specified), part of a micronutrient review; vs. low vs. normal zinc levels; supplementation vs. nonehigher infection rates with low zinc: worsened
71 Arentz et al. 2020systematic reviewZinc in various forms, alone or as adjunct; vs. Placebo or active controlrisk, duration and severity of SARS-CoV-2 infections: unclear

Further studies in this area: 78 120 122 127 156 168 215 283 299 303 315 317

Zinc and Common Cold: Human Studies

Preventively, zinc hardly changed the risk of colds in a large systematic review 9. Also in healthy adults, the number of colds remained the same 72. With an existing cold, the duration was shorter with zinc 972. The certainty of these data is low. Meta-analyses of lozenges with zinc acetate or zinc gluconate found a significantly shorter duration than with placebo 354445. Two of them evaluate the same patients 4445. A study with commercially available zinc acetate lozenges, however, found no difference 133. After discontinuation, the zinc group there even recovered more slowly 133. Zinc nasal spray with zinc lozenges did not shorten colds in a placebo-controlled study 268. Some participants had pain in the olfactory area 268. Mixed preparations do not allow conclusions about zinc alone. Zinc with high-dose vitamin C alleviated runny nose 123. An herbal formula with vitamin C and zinc shortened the symptoms 170. It is open which composition of lozenges works best 3544.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
9 Nault et al. 2024systematic review · 8,526 participantsZinc in various forms, mostly lozenges (gluconate, acetate, orotate); Zinc gluconate 45 to 276 mg/day; 4.5 to 21 days (treatment); follow-up 5 to 18 months (prevention); vs. PlaceboRisk of developing a cold: no difference (RR 0.93, 95% CI 0.85 to 1.01); Mean number of colds over 5 to 18 months: no difference (MD -0.90, 95% CI -1.93 to 0.12); Duration of colds in days: no difference (MD -0.63, 95)
11 Hunter et al. 2021systematic review · 5,446 participantsZinc formulations oral, intranasal or sublingual; not reported; not reported; vs. Placebo or active controlClinical colds following human rhinovirus inoculations: no difference (RR 0.96, 95% CI 0.77 to 1.21)
35 Hemilä et al. 2017meta-analysis · 575 participantsZinc lozenges of zinc acetate or zinc gluconate; >75 mg/day; 80-92 mg/day or 192-207 mg/day; vs. PlaceboDuration of the common cold: improved (33% (95% CI 21% to 45%) shorter); Duration of the common cold (zinc acetate): improved (shortened by 40%); Duration of the common cold (zinc gluconate): improved (shortened by 28%)
44 Hemilä et al. 2017meta-analysis · 199 participantszinc acetate lozenges; 80-92 mg/day elemental zinc; from symptom onset, assessed to day 5; vs. placebo lozengesrecovery rate (rate ratio): improved (3.1 (95% confidence interval, 2.1-4.7)); proportion recovered on day 5: improved (70% of the zinc patients had recovered compared with 27% of the placebo patients); number needed to treat on day 5: improved (2.3)
45 Hemilä et al. 2016meta-analysis · 199 participantsZinc acetate lozenges; vs. PlaceboDuration of common cold: improved (2.73 days (95% CI 1.8, 3.3 days) shorter); Duration of common cold: improved (2.94 days (95% CI 2.1, 3.8 days) reduction)
72 Wang et al. 2020systematic reviewOral zinc supplementation (form not stated); vs. Placebo/control or other micronutrientsCold duration: improved (reduce cold duration by 2.25 days (when zinc is provided singly, 95% CI: -3.39, -1.12)); Cold incidence: no difference; Symptom severity: no difference
123 Maggini et al. 2012randomised controlled · 94 participants1000 mg vitamin C plus 10 mg zinc; 1000 mg vitamin C + 10 mg zinc; 5 days of treatment; vs. Placeborhinorrhoea duration: no difference (nonsignificant reduction of rhinorrhoea duration (range 9-27%)); rhinorrhoea over 5 days: improved (significantly more efficient than placebo); symptom relief: improved (symptom relief was quicker)
133 Hemilä et al. 2020randomised controlled · 87 participantsZinc acetate lozenges (commercially available); 13 mg elemental zinc, six times per day; maximum 5 days; vs. Placebo lozenges with sucrose octa-acetateRecovery rate over 10 days: no difference (rate ratio for zinc vs placebo=0.68, 95% CI 0.42 to 1.08; p=0.10); Recovery rate in the 2 days after end of use: worsened (p=0.003)

Further studies in this area: 154 170 268 320

Zinc and Immune Function: Human Studies

Two meta-analyses of randomized trials found lower levels of the inflammatory marker C-reactive protein with zinc 5861. One concerned diabetes and prediabetes 58, the other also found lower interleukin-6 and tumor necrosis factor-alpha 61. In older nursing home residents with low serum zinc, serum zinc and the number of T cells increased with a higher zinc dose 222. The comparison was with a low zinc dose 222. In HIV patients with zinc deficiency, the activation marker soluble CD14 decreased with zinc gluconate, but other inflammatory markers did not 121. Two studies found no difference in CD4 cell count in HIV patients with zinc gluconate 94173. In COVID-19 patients, antibody levels were lower with zinc acetate than without zinc 156. In young children in Bangladesh, neither zinc tablets nor zinc-containing micronutrient powder changed gene expression or cytokines 119. A mixed preparation of yeast glucans with selenium and zinc caused antibodies to rise more after COVID-19 vaccination than placebo 155. What share zinc has in this is open. The findings mostly come from small studies in special groups and concern laboratory values. Whether this leads to fewer infections remains to be clarified.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
58 Nazari et al. 2024meta-analysisZinc supplementation (form not specified); vs. Control group (placebo/no supplementation)C-reactive protein: improved
61 Nazari et al. 2023meta-analysisZinc supplementation (form not specified); vs. Control group (placebo or no supplementation)C-reactive protein: improved; Interleukin-6: improved; Tumor necrosis factor-alpha: improved
69 Li et al. 2021meta-analysisVitamin and mineral supplements, including zinc; vs. Placebohs-CRP: improved (MD = - 1.29; 95% CI: - 1.82, - 0.76; P < 0.00001)
94 Freiberg et al. 2020randomised controlled · 254 participantsPharmacy-grade zinc gluconate vs. placebo; 15 mg/day men, 12 mg/day women; 18 months; vs. Placebo, double-blind randomizedCD4 cell count: no difference (AMD, 41.8 cells/mm3; 95% CI, -20.3 to 103.8 cells/mm3; P = .19)
97 Kewcharoenwong et al. 2022randomised controlled · 200 participantsTherapeutic dispersible zinc tablets (TZ), daily multiple micronutrient powder (MNP), daily preventive zinc tablets (PZ), placebo powder; 7, 10 or 20 mg/day elemental zinc; vs. Placebo powder (control)Plasma anti-E. coli IgG levels: improved (significantly increased compared with baseline); Anti-E. coli IgG avidity: improved (increased anti-E. coli IgG avidity in the control and PZ groups)
119 Hayman et al. 2021randomised controlled · 100 participantsZinc MNP (10 mg zinc) or dispersible zinc tablet (10 mg); 10 mg zinc daily; 24 weeks; vs. Placebo powderDifferential peripheral blood gene expression: no difference; Cytokine concentrations: no difference
121 Baissary et al. 2025randomised controlled · 95 participantsZinc gluconate tablets (90 mg elemental zinc) or placebo; 90 mg elemental zinc daily; 24 weeks; vs. Placebo, double-blind, randomized 2:1soluble CD14 (monocyte activation marker): improved (-56.31 ng/mL (-263.24; 134.19) vs 101.71 ng/mL (-90.50; 243.20); p = 0.021)
156 Gómez-Zorrilla et al. 2025randomised controlled · 71 participantsOral zinc acetate plus standard of care; 90 mg/day; 14 days; vs. Standard of care aloneAntibody levels at days 14 and 28: worsened

Further studies in this area: 173 222 289 301 315 318

Zinc and Diarrhoea in Children: Human Studies

In children with acute diarrhea, zinc shortened the duration in a meta-analysis 60. More children recovered than with placebo, also in persistent diarrhea 60. Another review reaches the same conclusion 48. Preventive zinc reduced the frequency and severity of diarrhea in young children, mostly with low zinc levels 107. A large review of preventive administration also found somewhat fewer diarrheas 4. For mortality from diarrhea, no confirmed difference was shown 34. In Laos, zinc had no overall effect on diarrhea in young children 78. Only in children over one and a half years did therapeutic zinc shorten the episodes 78. In addition to probiotics, zinc sulfate syrup shortened recovery time, but not illness severity 249. Most studies investigated zinc sulfate syrup in very different doses 4. It remains open which form and dose are most favorable for which age. A meta-analysis recommends lower doses because they caused vomiting less often 60.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
3 Rouhani et al. 2022meta-analysis · 237,068 participantsZinc supplementation (form not stated); ≥10 mg/day in subgroup analysis; Intervention <11 months, follow-up <1 year; vs. Placebo/control in RCTsMortality from diarrhea: no difference (0.85; 0.70, 1.03)
4 Imdad et al. 2023systematic review · 219,584 participantsPreventive zinc supplementation, mostly zinc sulfate syrup; mostly 10 mg to 15 mg daily; median follow-up 26 weeks; vs. no intervention, placebo, or waiting listMortality due to all-cause diarrhea: no difference (RR 0.95, 95% CI 0.69 to 1.31); Incidence of all-cause diarrhea: improved (RR 0.91, 95% CI 0.90 to 0.93)
48 De et al. 2026systematic review · 51 participantsZinc supplementation, therapeutic or prophylactic; heterogeneous dosing, not standardized; variable treatment duration; vs. placebo or control, per studyduration and severity of diarrheal episodes: improved (consistently reduced the duration and severity of diarrheal episodes)
60 Ali et al. 2024systematic reviewZinc supplementation (form not stated); low dose vs high dose compared; vs. Placebo or no zincProportion recovered in acute diarrhoea: improved (RR = 1.07; 95% CI = 1.03, 1.1); Duration of diarrhoea in acute diarrhoea: improved (MD = -13.27 hours; 95% CI = -17.66, -8.89); Proportion recovered in persistent diarrhoea: improved (RR = 1.75; 95% CI = 1.34, 2.30)
76 Edwards et al. 2025randomised controlled · 4,500 participantsZinc supplementation (salt form not stated); 5 mg, 10 mg or 20 mg daily; vs. lower vs. higher zinc doseany vomiting: no difference (1203 (26.7%)); vomiting with dehydration: worsened (RR: 1.45, 95% CI: 1.10-1.92); vomiting with underweight: worsened (RR: 1.22, 95% CI: 1.05-1.41)
78 Barffour et al. 2020randomised controlled · 3,407 participantsTherapeutic zinc, preventive zinc tablets, multiple micronutrient powder; TZ: 20 mg/d for 10 days; PZ: 7 mg/d; MNP: 10 mg zinc/d; 9 months; vs. PlaceboDiarrhea incidence: no difference (0.61 ± 0.01 episodes/100 days at risk); Diarrhea duration: no difference (2.12 ± 0.03 days/episode); Diarrhea incidence in children >18 months (TZ vs. MNP): improved (reduced by 24% (P = 0.035))
81 Islam et al. 2022randomised controlled · 2,886 participantsZinc in micronutrient powder or dispersible tablets; 4.1 mg or 10 mg zinc daily or alternating days; 24 weeks; vs. Placebo powderIncidence of diarrhea: no difference; Prevalence of diarrhea: no difference
107 Abd et al. 2022randomised controlled · 140 participantszinc supplement (form not stated); daily, amount not stated; 4 months; vs. placebocumulative incidence of diarrhea: improved (P < .05); number of diarrhea episodes per child: improved (P < .05); frequency of stools per day: improved (P < .05)

Further studies in this area: 249 316

Zinc and Skin: Human Studies

In hemodialysis patients, zinc gluconate alleviated itching in a randomized placebo-controlled trial, but not dry skin 132. A systematic review sees only limited evidence that ingested zinc heals skin warts 75. This is most likely the case with zinc deficiency 75. In children with Hirschsprung disease, the skin was less often sore after surgery with zinc 188. With the cancer drug regorafenib, hand-foot skin reactions occurred less often with zinc 258. Combination products also do not allow any statement about zinc alone here. These include combinations with glutathione and vitamin C 137, with alpha-lipoic acid and biotin 219, as well as an acne care product with pomegranate extract 231. The skin studies are small and short and use different zinc forms.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
75 Simonart et al. 2012systematic reviewZinc (systemic); vs. Placebo or other systemic therapiesTotal clearance of warts: improved (limited evidence)
132 Tavassoli et al. 2024randomised controlled · 87 participantsZinc gluconate; 210 mg zinc gluconate (30 mg elemental zinc) per day; 12 weeks; vs. PlaceboPruritus: improved (-0/52 (-0/82 to - 0/22)); Xerosis: no difference
137 Sitohang et al. 2021randomised controlled · 83 participantsOral glutathione supplement with zinc aspartate; 12 weeks; vs. Placebo capsulesSpot ultraviolet reduction in subgroups: no difference (not statistically significant); Spot polarization reduction: no difference (not statistically significant); Skin tone improvement: no difference (not statistically significant)
188 Ibrahim et al. 2025randomised controlled · 50 participantsZinc (form not specified); preoperative; vs. Control group without zincSkin excoriation: improved (8% vs. 32%)
258 Huang et al. 2023randomised controlledZinc supplementation; first 8 weeks of treatment; vs. randomized control groupIncidence of grade ≥2 hand-foot skin reaction: improved
288 Towersey et al. 2023study · 51 participantscleansing gel with salicylic acid 2%, zinc gluconate 0.2%, lipohydroxy acid 0.05%; daily use, amount not reported; 84 days; vs. no control group, open-labeltotal lesion count: improved (-56.3%); non-inflammatory lesions: improved (-64.0%); inflammatory lesions: improved (-48.2%)
302 Lalosevic et al. 2023case-control studySerum zinc measurement, no zinc supplementation; vs. Alopecia areata group vs. healthy controlsSerum zinc concentration: worsened (p = 0.017); Prevalence of zinc deficiency: worsened (p = 0.011); Correlation between serum zinc and disease severity: worsened (ρ = 0.006)

Zinc and Taste: Human Studies

In unexplained taste disorders, zinc gluconate improved taste in a randomized placebo-controlled study 200. A controlled study with zinc picolinate showed a better result in a taste test with filter paper disk method in zinc deficiency taste disorders 269. However, subjective complaints and the whole-mouth test did not improve more than with placebo 269. A second double-blind study with zinc picolinate showed the same pattern 277. A meta-analysis with various zinc salts found improvement in taste disorders more often than with control 26. The individual studies are small and use different zinc forms. It is open which form and dose help for which cause.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
26 Mozaffar et al. 2023meta-analysis · 938 participantsZinc (sulfate, gluconate, picolinate, polaprezinc, acetate); 17–86.7 mg elemental zinc daily; three to six months; vs. Control groupImprovement in taste disorder: improved (RR = 1.38; 95% CI: 1.16, 1.64, p=0.0002); Improvement in taste perception in chronic renal disease (zinc acetate): improved (RR = 26.69, 95% CI = 5.52-129.06, p < 0.0001)
200 Heckmann et al. 2005randomised controlled · 50 participantsZinc gluconate or placebo (lactose); 140 mg/day; vs. Placebo (lactose)Gustatory function: improved (p <0.001); Severity of dysgeusia: improved (p <0.05)
269 Sakai et al. 2002controlled · 73 participantszinc picolinate, oral capsule; 29 mg zinc picolinate three times daily; 3 months; vs. placebo, double-blindimprovement in subjective symptoms: no difference; whole-mouth taste sensation: no difference; taste assessment by filter paper disk method: improved (significantly better improvement)
277 Sakai et al. 1995controlledZinc picolinate; vs. PlaceboImprovement by filter-paper disk method: improved; Total subjective recovery: no difference; Improvement by whole mouth method: no difference
312 Nin et al. 2024reviewOral zinc therapy: polaprezinc (off-label) and zinc acetate hydrate; vs. Various treatments in patients under and over 65 yearsEfficacy of zinc therapy for taste disorders: unclear (low-level evidence); Efficacy of various treatments in older vs. younger patients: no difference (no significant difference)
316 Santos et al. 2022reviewZinc supplements (form not specified); ∼50-150 mg/day elemental zinc in adults; vs. no comparison, reviewzinc supplementation in taste disorders: improved

Zinc and Wound Healing: Human Studies

The controlled studies on wound healing tested zinc only in combinations. A skin care product with prebiotics, panthenol and zinc shortened healing time after cryotherapy 149. In pressure ulcers, polaprezinc, a zinc-carnosine complex, worked better than no treatment 271. L-carnosine alone, however, worked just as well 271. A liquid nutritional supplement with arginine, vitamin C and zinc did not significantly reduce pressure ulcers 240. From these mixtures, no independent effect of zinc can be derived. A review on supply during operations links low zinc levels with slower wound healing and more infections 50. Whether targeted zinc administration changes this is still open 50. The studies are small and short.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
36 De et al. 2026systematic review · 544 participantsZinc L-carnosine in mouthwashes, lozenges, mucoadhesive suspensions; vs. Control groups without ZnCImproved surgical wound healing: improved
50 Banerjee et al. 2026systematic reviewzinc (form not specified), part of a micronutrient review; vs. low vs. normal zinc levels; supplementation vs. nonedelayed healing with low zinc: worsened
240 Sánchez-Sánchez et al. 2026randomised controlledhypercaloric hyperproteic ONS with fiber, omega-3, L-arginine, nucleotides, vitamin C and zinc; 15 and 30 days; vs. hypercaloric hyperproteic ONS with fiber without enrichmentfrequency of pressure-related injuries: no difference (did not reach statistical significance); high risk proportion: no difference (72.5% vs 40.9%); PUSH scale: no difference
271 Sakae et al. 2013controlled · 42 participantsPolaprezinc (zinc-L-carnosine complex) orally; 150 mg/d polaprezinc (34 mg zinc, 116 mg L-carnosine); maximum 4 weeks; vs. untreated control and L-carnosine group (116 mg/d)mean weekly improvement in PUSH score: no difference (1.8 ± 0.2, P = .009)
298 Bechara et al. 2026cohort studySerum zinc (no zinc supplementation reported); 12 months follow-up; vs. zinc deficiency vs. adequate zinc levelswound healing or time to healing: no difference

Zinc: Further Outcomes in Studies

Further studies tested zinc for very different questions, from metabolic values to pregnancy and infections. Meta-analyses in diabetes and prediabetes found more favorable blood sugar or blood lipid levels with zinc 1721242558. One of them saw a slight increase in LDL cholesterol 25. A broader meta-analysis found no difference in LDL cholesterol, blood pressure and liver enzymes 61. These are laboratory values; whether this leads to fewer cardiovascular diseases remains to be clarified. In menstrual pain, zinc alleviated pain more than placebo in a meta-analysis 28. Mixed preparations concerned, for example, pregnancy 2 or vitamin A in tuberculosis 20; the share of zinc remains open there.

StudyDesign · participantsPreparation · dose · duration · comparisonResult
1 An et al. 2022meta-analysis · 883,627 participantsZinc supplementation (form not specified); vs. Control group without zincCardiovascular risk factors: improved (moderate- to high-quality evidence for reducing CVD risk factors)
2 Keats et al. 2021systematic review · 451,723 participantsZinc as single nutrient and multiple micronutrient supplements; vs. Folic acid, iron-folic acid, multiple micronutrients, lipid-based nutrientsMaternal anaemia (IFA vs. folic acid): improved (average risk ratio (RR) 0.52, 95% CI 0.41 to 0.66); Low birthweight (IFA vs. folic acid): improved (average RR 0.88, 95% CI 0.78 to 0.99); Low birthweight (MMN vs. iron with/without folic acid): improved (average RR 0.85, 95% CI 0.77 to 0.93)
3 Rouhani et al. 2022meta-analysis · 237,068 participantsZinc supplementation (form not stated); ≥10 mg/day in subgroup analysis; Intervention <11 months, follow-up <1 year; vs. Placebo/control in RCTsAll-cause mortality: improved (SRR: 0.84, 95% CI: 0.74, 0.96); All-cause mortality with follow-up <1 year: improved (0.46; 0.33, 0.63); All-cause mortality at dose ≥10 mg/day: improved (0.56; 0.42, 0.75)
4 Imdad et al. 2023systematic review · 219,584 participantsPreventive zinc supplementation, mostly zinc sulfate syrup; mostly 10 mg to 15 mg daily; median follow-up 26 weeks; vs. no intervention, placebo, or waiting listAll-cause mortality: no difference (RR 0.93, 95% CI 0.84 to 1.03); Mortality due to malaria: improved (RR 0.90, 95% CI 0.77 to 1.06); Height: improved (SMD 0.12, 95% CI 0.09 to 0.14)
5 Shahrokhi et al. 2024meta-analysis · 163,909 participantsZinc levels in serum, hair, nail, prostatic fluid/tissue; zinc intake; vs. Prostate cancer patients vs. healthy controlsSerum zinc level: worsened (SMD: -1.11; 95% CI: -1.67, -0.56); Hair zinc level: worsened (SMD: -1.31; 95% CI: -2.19, -0.44); Prostatic fluid or tissue zinc level: worsened (SMD: -3.70; 95% CI: -4.90, -2.49)
6 Carducci et al. 2021systematic review · 18,000 participantsZinc supplementation (form not reported); vs. No zinc supplementation or placeboPreterm births: no difference (RR 0.87, 95% CI 0.74 to 1.03); Stillbirth: no difference (RR 1.22, 95% CI 0.80 to 1.88); Perinatal deaths: no difference (RR 1.10, 95% CI 0.81 to 1.51)
7 Sajedi et al. 2020systematic review · 11,559 participantsZinc supplementation alone or with iron co-supplementation; Follow-up up to 9 years; vs. Placebo or control (not specified)Mental development (Bayley Scales II, 6 and 12 months): no difference; Motor development (Bayley Scales II, 6 and 12 months): no difference; Long-term development in preschool and school-age children: no difference
8 Shi et al. 2026meta-analysis · 10,262 participantsMagnesium-zinc-calcium-vitamin D supplement; vs. Standard controlCesarean section rate: no difference (RR = 0.44, 95% CI: 0.15, 1.29)

Further studies in this area: 10 11 13 14 15 16 17 18 19 20 21 22 23 24 25 27 28 29 30 31 32 33 34 36 37 38 39 40 41 42 43 46 47 48 49 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 73 74 77 79 80 81 82 83 84 85 86 87 88 89 91 92 94 95 96 98 99 100 101 102 103 104 105 106 108 109 110 111 112 113 114 115 116 117 118 121 122 124 125 126 128 129 130 131 132 134 135 136 138 139 140 141 142 143 144 145 146 147 148 150 151 152 153 157 158 159 160 161 162 163 164 165 166 167 169 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 216 217 218 220 221 223 224 225 226 227 228 229 230 232 233 234 235 236 237 238 239 241 242 243 244 246 247 248 250 251 252 253 254 255 256 257 259 260 261 262 263 264 265 266 267 269 270 272 273 274 275 276 277 278 279 280 281 282 284 285 286 287 289 290 291 292 293 294 295 296 297 299 300 301 304 305 306 307 308 309 310 311 313 314 316 318 319

4. How Is Zinc Dosed? Preparation, Dose and Duration in Studies

The studies predominantly used oral zinc forms such as zinc sulfate, zinc gluconate, zinc citrate, zinc picolinate and zinc acetate, sometimes also sublingual, intranasal or as lozenges. Individual investigations tested zinc oxide for external use as well as zinc-L-carnosine in mouth rinses and adhesive suspensions. Form, amount and duration of intake varied considerably between the studies, which limits comparability.

Preparation or formDoseDurationStudy
Zinc supplementation (salt form not stated)5 mg, 10 mg or 20 mg daily—76
Oral AREDS2 nutrient supplements with lower versus higher zinc dosage—Median 5 years77
Therapeutic zinc, preventive zinc tablets, multiple micronutrient powderTZ: 20 mg/d for 10 days; PZ: 7 mg/d; MNP: 10 mg zinc/d9 months78
Daily preventive zinc tablets, multiple micronutrient powders, therapeutic zinc supplements, or placebo7 mg/day, 10 mg/day (MNP), 20 mg/day for 10 days (TZ)~36 weeks follow-up79
Daily zinc tablets, micronutrient powder with zinc, therapeutic zinc supplementation7 mg/d zinc; 10 mg/d zinc in powder; 20 mg/d zinc for 10 days per diarrhea episodeapproximately 9 months80
Zinc in micronutrient powder or dispersible tablets4.1 mg or 10 mg zinc daily or alternating days24 weeks81
Daily zinc (25 mg) and vitamin A (2500 IU) vs. placebo25 mg zinc dailyFrom first trimester to delivery82
Quintuply-fortified salt with zinc, iron, vitamin B12, folic acid, iodine—12 months83
Quintuply-fortified salt with zinc, iron, vitamin B12, folic acid, iodineSalt disappearance 6.0 g/adult female equivalent/day, zinc dose not reported12 months84
Chispuditos®, micronutrient-fortified atole drink (9 mg zinc, 12.5 mg iron)9 mg zinc per day (part of mixture)18 months85
Oral nutrition supplement with multi-minerals and vitamins (contains zinc)—12 weeks86
Quintuply-fortified salt (zinc, B-12, folate, iodine, iron)—12 months87
Daily zinc tablets (7 mg) or zinc-containing multiple micronutrient powder (10 mg zinc + 13 other micronutrients) or placebo7 mg zinc daily (PZ) or 10 mg zinc daily (MNP)9 months (36 weeks)88
Oral zinc gluconate supplementation15 mg/d or 30 mg/d6 months89
EZC Pak: echinacea-zinc-vitamin C combination, with or without vitamin D—5 days90

5. Is Zinc Safe? Side Effects in Studies

In the treatment of respiratory infections, mild side effects occurred more often with zinc than with placebo 91114. Nausea and irritation in the mouth and nose are mentioned 1114. With zinc acetate lozenges, more participants reported side effects than with placebo 133. A zinc nasal spray caused pain in the olfactory area in some participants 268. The authors warn against putting zinc into the nose because of reported loss of smell 268. Serious adverse events were not observed in several evaluations 1044. In children, vomiting occurred more often with zinc than without zinc 460. Lower doses caused vomiting less often 6076. In menstrual pain, side effects did not differ in a confirmed way from placebo 28.

StudyReported side effects
4 Imdad et al. 2023more participants with at least one vomiting episode (RR 1.29)
7 Sajedi et al. 2020no adverse effects reported
9 Nault et al. 2024Unpleasant taste, loss of smell, vomiting, stomach cramps, diarrhoea (reported)
10 Gulani et al. 2014no serious adverse events; a small minority of children vomited shortly after ingestion
11 Hunter et al. 2021Non-serious adverse events (nausea, irritation) more frequent
13 Zhou et al. 2024Safety assessed via SUCRA ranking
14 Hunter et al. 2020no serious AEs; non-serious AEs such as nausea, mouth or nasal irritation
15 Ghadirzadeh et al. 2025No diarrhea, rash, or vomiting; publication bias found
16 Yadav et al. 2025No differences in adverse events
18 Abdollahi et al. 2020not reported
23 Wang et al. 2026Zinc supplementation reported as safe
28 Hsu et al. 2024no significant difference vs placebo (OR 2.54; 95% CI 0.78-8.26; p = 0.122)

6. What Remains Open: Limits of the Evidence

  • Most data come from countries with widespread zinc deficiency and predominantly concern children, so transferability to adults without zinc deficiency remains open.
  • Form, dose and duration of zinc intake are inconsistent between the studies, which makes direct comparison difficult.
  • Many individual studies are small and short, and the results often differ greatly between studies.
  • Combination products with other substances do not allow any statement about the effect of zinc alone.
  • Preventive administration and treatment of an existing illness sometimes led to different results, for example with colds 9.

7. Bottom Line: What Is Established About Zinc

Zinc is a trace element that the body cannot produce itself and can store only to a limited extent. The clearest benefits are shown by controlled trials and meta-analyses for diarrhea and respiratory infections in children, mostly in regions with widespread zinc deficiency. For colds, the reviews contradict each other; for taste disorders and skin diseases, there are individual smaller studies with favorable results. The results depend strongly on zinc form, dose, duration and the population studied. Combination products with other substances do not allow any statement about the effect of zinc alone. Tolerability is predominantly described as good, although mild gastrointestinal side effects such as nausea and vomiting occurred more frequently with zinc.

Frequently Asked Questions

How well has Zinc been studied in humans?

We evaluated 330 human studies on Zinc, including 198 randomised controlled trials and 75 meta-analyses or systematic reviews; the controlled studies include 42,118 participants in total. As of 5 October 2026.

Does Zinc help with respiratory tract infections? What the studies show

We evaluated 6 meta-analyses or systematic reviews, 7 controlled studies and 7 further studies; the controlled studies include 3,862 participants in total. Result of the controlled studies: mostly improved. Strength of evidence under our published rules: high. Sources: 341112

Does Zinc help with common cold? What the studies show

We evaluated 6 meta-analyses or systematic reviews, 4 controlled studies and 2 further studies; the controlled studies include 320 participants in total. Result of the controlled studies: mostly no difference. Strength of evidence under our published rules: high. Sources: 9113544

Does Zinc help with immune function? What the studies show

We evaluated 2 meta-analyses or systematic reviews, 7 controlled studies and 5 further studies; the controlled studies include 811 participants in total. Result of the controlled studies: mixed. Strength of evidence under our published rules: high. Sources: 58616994

Does Zinc help with diarrhoea in children? What the studies show

We evaluated 4 meta-analyses or systematic reviews, 5 controlled studies and one further study; the controlled studies include 10,933 participants in total. Result of the controlled studies: mixed. Strength of evidence under our published rules: high. Sources: 344860

Does Zinc help with skin? What the studies show

We evaluated one meta-analysis or systematic review, 4 controlled studies and 2 further studies; the controlled studies include 220 participants in total. Result of the controlled studies: mostly improved. Strength of evidence under our published rules: high. Sources: 75132137188

Does Zinc help with taste? What the studies show

We evaluated one meta-analysis or systematic review, 3 controlled studies and 2 further studies; the controlled studies include 123 participants in total. Result of the controlled studies: mostly no difference. Strength of evidence under our published rules: moderate. Sources: 26200269277

What is zinc and what is it studied for?

Zinc is a trace element that the body cannot produce itself and can store only to a limited extent. It is taken in through food and additionally supplied in the form of salts or compounds bound to organic carriers. In studies, zinc is investigated among other things for respiratory infections, skin diseases, diarrhea in children and colds.

Which zinc forms were used in the studies?

The studies predominantly used zinc sulfate, zinc gluconate, zinc citrate, zinc picolinate and zinc acetate, sometimes orally, sublingually or intranasally. Individual investigations tested zinc oxide for external use as well as zinc-L-carnosine in mouth rinses and adhesive suspensions. Form, amount and duration of intake influence absorption and varied considerably between the studies.

Does zinc show an effect for colds?

The reviews contradict each other: Preventively, zinc hardly changed the risk of colds 9, but with an existing cold the duration was shorter 972. The certainty of these data is low. A meta-analysis on zinc acetate lozenges reported faster recovery 44. A randomized controlled trial, by contrast, found no difference and even slower recovery after the end of intake 133. The results vary depending on zinc form, administration and study quality.

What side effects do the studies report?

In the treatment of respiratory infections, mild side effects occurred more often with zinc than with placebo 91114. Nausea and irritation in the mouth and nose are mentioned 1114. With zinc acetate lozenges, more participants reported side effects than with placebo 133. A zinc nasal spray caused pain in the olfactory area in some participants 268. The authors warn against putting zinc into the nose because of reported loss of smell 268. Serious adverse events were not observed in several evaluations 1044. In children, vomiting occurred more often with zinc than without zinc 460. Lower doses caused vomiting less often 6076. In menstrual pain, side effects did not differ in a confirmed way from placebo 28.

What can be derived from combination products with zinc?

Combination products with other substances such as iron, vitamin C, vitamin D or selenium do not allow any statement about the effect of zinc alone. A randomized controlled trial on a combination product of echinacea, zinc and vitamin C found a shorter duration of illness 90. A large review found that iron given at the same time weakened the benefit of zinc in children 4.

Sources

  1. 1
    An P, Wan S, Luo Y, Luo J, Zhang X, Zhou S et al. · 2022
  2. 2
  3. 3
  4. 4
  5. 5
    Shahrokhi Nejad S, Golzari Z, Zangiabadian M, Salehi Amniyeh Khozani AA, Ebrahimi R, Nejadghaderi SA et al. · 2024
  6. 6
  7. 7
  8. 8
  9. 9
    Nault D, Machingo TA, Shipper AG, Antiporta DA, Hamel C, Nourouzpour S et al. · 2024
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
    Ghadirzadeh B, Afshar M, Afraie M, Moradveisi B, Moradi Y · 2025
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    Chitiki GDR, Pandita H, Mehta PK, Deshwali A, Ranjan A, Sood H et al. · 2026
  31. 31
  32. 32
  33. 33
    Mbanefo NR, Uwaezuoke SN, Eneh CI, Odimegwu CL, Chikani UN, Muoneke UV et al. · 2023
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
    Ceballos-Rasgado M, Brazier AKM, Gupta S, Moran VH, Pierella E, Fekete K et al. · 2025
  58. 58
    Nazari M, Nikbaf-Shandiz M, Pashayee-Khamene F, Bagheri R, Goudarzi K, Hosseinnia NV et al. · 2024
  59. 59
    Jazinaki MS, Gheflati A, Moghadam MRSF, Hadi S, Razavidarmian M, Nezhad MY et al. · 2024
  60. 60
  61. 61
    Nazari M, Ashtary-Larky D, Nikbaf-Shandiz M, Goudarzi K, Bagheri R, Dolatshahi S et al. · 2023
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
    Borges L, Gennari-Felipe M, Dias BB, Hatanaka E · 2021
  68. 68
  69. 69
  70. 70
  71. 71
    Arentz S, Hunter J, Yang G, Goldenberg J, Beardsley J, Myers SP et al. · 2020
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
    Stewart-Knox BJ, Rae G, Simpson EE, McConville C, O'Connor J, Polito A et al. · 2011
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
    Reino-Gelardo S, Palop-Cervera M, Aparisi-Valero N, Espinosa-San Miguel I, Lozano-Rodríguez N, Llop-Furquet G et al. · 2023
  103. 103
    van der Burg KP, Cribb L, Firth J, Karmacoska D, Mischoulon D, Byrne GJ et al. · 2020
  104. 104
    Afzali A, Goli S, Moravveji A, Bagheri H, Mirhosseini S, Ebrahimi H · 2021
  105. 105
  106. 106
  107. 107
  108. 108
  109. 109
  110. 110
  111. 111
  112. 112
  113. 113
  114. 114
  115. 115
  116. 116
  117. 117
    Obiagwu HI, Eleje GU, Obiechina NJA, Nwosu BO, Udigwe GO, Ikechebelu JI et al. · 2023
  118. 118
  119. 119
  120. 120
  121. 121
  122. 122
  123. 123
  124. 124
    [Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections.]
    Salinas-Casado J, Méndez-Rubio S, Esteban-Fuertes M, Gómez-Rodríguez A, Vírseda-Chamorro M, Luján-Galán M et al. · 2018
  125. 125
  126. 126
  127. 127
    Atta A, Aftab A, Shafqat A, Yousuf MH, Ahmed A, Pirzada H et al. · 2024
  128. 128
  129. 129
  130. 130
  131. 131
  132. 132
  133. 133
  134. 134
  135. 135
  136. 136
  137. 137
    Evaluating Oral Glutathione Plus Ascorbic Acid, Alpha-lipoic Acid, and Zinc Aspartate as a Skin-lightening Agent: An Indonesian Multicenter, Randomized, Controlled Trial
    Sitohang IBS, Anwar AI, Jusuf NK, Arimuko A, Norawati L, Veronica S · 2021
  138. 138
  139. 139
  140. 140
  141. 141
  142. 142
  143. 143
  144. 144
  145. 145
    [Yiqi Zhujing granule for idiopathic oligoasthenozoospermia: a clinical study]
    Huang XF, He Y, Fan Q, Wang Q, Ning KQ · 2013
  146. 146
    Seirafian S, Feizi A, Shahidi S, Badri SS, Rouhani MH, Najafabadi PP et al. · 2023
  147. 147
  148. 148
  149. 149
  150. 150
  151. 151
  152. 152
    The effect of Breezy candy on halitosis: a double-blind, controlled, and randomized study
    Barak S, Katz J · 2012
  153. 153
  154. 154
  155. 155
  156. 156
    Gómez-Zorrilla S, Sendra E, Du J, Espona M, Fierro-Villegas A, Siverio A et al. · 2025
  157. 157
  158. 158
  159. 159
  160. 160
  161. 161
  162. 162
  163. 163
  164. 164
  165. 165
    Liu YL, Zhang MN, Tong GY, Sun SY, Zhu YH, Cao Y et al. · 2017
  166. 166
  167. 167
    A Randomized, Placebo-controlled Clinical Study Evaluating a Dietary Supplement for Hair Growth
    Martin-Biggers J, Barbosa Bueno de Campos ME · 2024
  168. 168
  169. 169
  170. 170
  171. 171
    Piccirillo M, Mennini M, Felici E, Mauro A, Bernardo L, Baldassarre ME et al. · 2026
  172. 172
  173. 173
    Osuna-Padilla IA, Rodríguez-Moguel NC, Aguilar-Vargas A, Tolentino-Dolores M, Perichart-Perera O, Ahumada-Topete V et al. · 2024
  174. 174
  175. 175
  176. 176
  177. 177
    Asghari S, Hosseinzadeh-Attar MJ, Alipoor E, Sehat M, Mohajeri-Tehrani MR · 2019
  178. 178
    Payahoo L, Ostadrahimi A, Mobasseri M, Khaje Bishak Y, Farrin N, Asghari Jafarabadi M et al. · 2013
  179. 179
    Mousa N, Abdel-Razik A, Zaher A, Hamed M, Shiha G, Effat N et al. · 2016
  180. 180
  181. 181
    Antoniotti V, Partenope C, Solito A, Mancioppi V, Baima J, Medina F et al. · 2025
  182. 182
    Ostadmohammadi V, Samimi M, Mobini M, Zarezade Mehrizi M, Aghadavod E, Chamani M et al. · 2019
  183. 183
  184. 184
  185. 185
    Dirajlal-Fargo S, Yu J, Kulkarni M, Sattar A, Funderburg N, Barkoukis H et al. · 2019
  186. 186
    Vázquez-Lorente H, Molina-López J, Herrera-Quintana L, Gamarra-Morales Y, Quintero-Osso B, López-González B et al. · 2022
  187. 187
  188. 188
  189. 189
  190. 190
    Mousa A, Elgarhi I, Ibrahim B, Atalla E, Abdel-Rasheed M, Nagy O et al. · 2025
  191. 191
  192. 192
    Liu E, Manji KP, Kirby MA, Kisenge R, Lauer JM, Fawzi WW et al. · 2024
  193. 193
    The Efficacy of Cryotherapy and Zinc Gluconate in Management of Anogenital Warts: A Randomized Double-Blind, Split-Side, Placebo-Controlled Trial
    Ghahartars M, Sahaf A, Parvar SY, Ahramiyanpour N · 2023
  194. 194
  195. 195
  196. 196
  197. 197
  198. 198
  199. 199
  200. 200
    Heckmann SM, Hujoel P, Habiger S, Friess W, Wichmann M, Heckmann JG et al. · 2005
  201. 201
  202. 202
    Pecoraro L, Zoller T, Atkinson RL, Nisi F, Antoniazzi F, Cavarzere P et al. · 2022
  203. 203
  204. 204
    Togni L, Sparabombe S, Mascitti M, Barlattani A, Isola G, Lo Russo L et al. · 2026
  205. 205
  206. 206
    Alkaya B, Kayhan HG, Demirbilek F, Sahin M, Totik N, Ozcan M et al. · 2025
  207. 207
  208. 208
  209. 209
  210. 210
    Oliveira RG, Achcar-Feih MC, Nogueira-Pileggi V, Carnevale-Silva A, Carmona F, Aragon DC et al. · 2025
  211. 211
  212. 212
    Munk DE, Lund Laursen T, Teicher Kirk F, Vilstrup H, Ala A, Gormsen LC et al. · 2022
  213. 213
  214. 214
  215. 215
  216. 216
  217. 217
  218. 218
    Balasubramanian A, Holbrook JT, Canning BJ, Que LG, Castro M, Make BJ et al. · 2023
  219. 219
  220. 220
  221. 221
    Abbasinazari M, Alavian SM, Behnava B, Asgharinia M, Salimi S, Keshvari M et al. · 2014
  222. 222
  223. 223
    Leal-Martínez F, Franco D, Peña-Ruiz A, Castro-Silva F, Escudero-Espinosa AA, Rolón-Lacarrier OG et al. · 2020
  224. 224
  225. 225
  226. 226
    Itagaki M, Saruta M, Saijo H, Mitobe J, Arihiro S, Matsuoka M et al. · 2014
  227. 227
  228. 228
  229. 229
  230. 230
  231. 231
  232. 232
  233. 233
  234. 234
    Jäger R, Purpura M, Davis J, Keratsopoulos N, Parra ME, Secrest AH et al. · 2024
  235. 235
    Barrie SA, Wright JV, Pizzorno JE, Kutter E, Barron PC · 1987
  236. 236
    Pizzo G, Licata ME, La Cara M, Pizzo I, Guiglia R, Melilli D · 2007
  237. 237
  238. 238
  239. 239
  240. 240
  241. 241
    Keenan TDL, Agrón E, Keane PA, Domalpally A, Chew EY, Age-Related Eye Disease Study Research Group et al. · 2025
  242. 242
  243. 243
  244. 244
  245. 245
  246. 246
    Estorninos E, Lawenko RB, Lebumfacil JD, Posecion JEWC, Delos Reyes VC, Petit-Jean A et al. · 2025
  247. 247
  248. 248
  249. 249
  250. 250
  251. 251
    Nasrollahzadeh J, Makiabadi E, Reza Shahparvari M, Nilghaz M, Narimani B, Rajabpour Ranjbar Y · 2024
  252. 252
    Noce A, Marrone G, Di Lauro M, Vita C, Montalto G, Giorgino G et al. · 2024
  253. 253
  254. 254
  255. 255
  256. 256
  257. 257
    Portillo Siqueiros EY, Santellano-Estrada E, Flores Villalobos MÁ, Roacho Soto MG, Martínez Flórez S · 2024
  258. 258
  259. 259
  260. 260
  261. 261
    García-Guerra A, Rivera JA, Neufeld LM, Quezada-Sánchez AD, Dominguez Islas C, Fernández-Gaxiola AC et al. · 2022
  262. 262
    Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial
    Mazza A, Cicero AF, Ramazzina E, Lenti S, Schiavon L, Casiglia E et al. · 2016
  263. 263
    Jiang RS, Twu CW, Liang KL · 2015
  264. 264
  265. 265
  266. 266
  267. 267
    Effect of dietary zinc and phytase supplementation on botulinum toxin treatments
    Koshy JC, Sharabi SE, Feldman EM, Hollier LH, Patrinely JR, Soparkar CN · 2012
  268. 268
    Ineffectiveness of zinc gluconate nasal spray and zinc orotate lozenges in common-cold treatment: a double-blind, placebo-controlled clinical trial
    Eby GA, Halcomb WW · 2006
  269. 269
  270. 270
  271. 271
  272. 272
  273. 273
  274. 274
  275. 275
  276. 276
    Anderson RA, Roussel AM, Zouari N, Mahjoub S, Matheau JM, Kerkeni A · 2001
  277. 277
  278. 278
  279. 279
  280. 280
  281. 281
    Fortin S, Razafindratsima Y, Razakandrainy A, Randremanana R, Ralison C, Baldwin D et al. · 2026
  282. 282
  283. 283
  284. 284
  285. 285
    Vogel-González M, Talló-Parra M, Herrera-Fernández V, Pérez-Vilaró G, Chillón M, Nogués X et al. · 2021
  286. 286
    Zinc Deficiency Among Children Living with HIV on Antiretroviral therapy in Lagos, Nigeria
    Fakile UO, Akinsete AM, Akintan PE, Oyenusi EE, Abdulraheem KS, Temiye EO · 2025
  287. 287
  288. 288
  289. 289
    Roeth E, Morris M, Reynolds AP, Reynolds EM, Hungerford R, Livingston EJ et al. · 2025
  290. 290
  291. 291
  292. 292
  293. 293
    Kamel A, Abdelseed H, Albalawi Y, Aslsalameen E, Almutairi Y, Alkattan A · 2020
  294. 294
    Brocard A, Quereux G, Moyse D, Dreno B · 2010
  295. 295
  296. 296
  297. 297
  298. 298
  299. 299
    Huang SH, Weng HL, Hung KC, Ho CN, Tsai WW, Lai YC et al. · 2025
  300. 300
  301. 301
  302. 302
    Lalosevic J, Gajic-Veljic M, Lalosevic Misovic J, Nikolic M · 2023
  303. 303
    Dinardo G, Indolfi C, Klain A, Grella C, Tosca MA, Miraglia Del Giudice M et al. · 2026
  304. 304
  305. 305
  306. 306
  307. 307
    Tekeoğlu İ, Şahin MZ, Kamanlı A, Nas K · 2025
  308. 308
  309. 309
  310. 310
  311. 311
  312. 312
  313. 313
  314. 314
    Berg Y, Gabay E, Božić D, Shibli JA, Ginesin O, Asbi T et al. · 2024
  315. 315
    Firouzi S, Pahlavani N, Navashenaq JG, Clayton ZS, Beigmohammadi MT, Malekahmadi M · 2022
  316. 316
  317. 317
  318. 318
    Scarpellini E, Balsiger LM, Maurizi V, Rinninella E, Gasbarrini A, Giostra N et al. · 2022
  319. 319
  320. 320

Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.

International Health Research · https://ih-research.com/en/knowledge/zinc/ · Last updated: 2026-10-15